Hubert Birner
Directeur/Membre du Conseil chez CENTOGENE N.V.
Provenance du réseau au premier degré de Hubert Birner
| Entité | Type d'entité | Industrie | |
|---|---|---|---|
| Public Company | Miscellaneous Commercial Services | 41 | |
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital GmbH (TVMC) is an international venture capital firm headquartered in Munich, Germany. Founded in 1983, the firm was formerly known as Techno Venture Management.
34
| Private Company | Investment Managers | 34 |
| Subsidiary | Pharmaceuticals: Major | 20 | |
TransMolecular, Inc.
 TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs.
12
| Extinct | Biotechnology | 12 |
Horizon Pharma, Inc.
 Horizon Pharma, Inc. Pharmaceuticals: MajorHealth Technology Horizon Pharma, Inc. discovers and develops medicines for the treatment of chronic inflammatory diseases. It is a specialty pharmaceutical company that has developed and is commercializing DUEXIS and RAYOS, both of which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company products include DUEXIS (ibuprofen and famotidine) Tablets, is a proprietary, single-tablet combination of the non-steroidal anti-inflammatory drug ibuprofen and the histamine H2-receptor antagonist famotidine; RAYOS (prednisone) delayed-release tablets, known as LODOTRA outside the U.S., is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults, particularly when accompanied by morning stiffness. Horizon Pharma was founded on March 23, 2010 and is headquartered in Deerfield, IL.
11
| Extinct | Pharmaceuticals: Major | 11 |
SpePharm Holding BV
 SpePharm Holding BV Pharmaceuticals: MajorHealth Technology SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market. Particular therapeutic areas of interest are in oncology and hematology, critical and supportive care. SpePharm aims to be the preferred partner for pharmaceutical and biotechnology companies, especially those from outside of Europe, seeking to maximize product and commercial opportunities within Europe. The vision of SpePharm is to become a leading specialty pharmacy company offering the first truly pan-European commercial platform for high value niche hospital and specialist products. The company was founded in September 2006 by Jean-François Labbé together with leading life-science investment firms, TVM Capital (Germany) and Signet Healthcare Partners, part of the Sanders Morris Harris Group Inc (USA). SpePharm headquarters are located in Amsterdam, The Netherlands. Its European operations are run from its French subsidiary, SpePharm SAS, in Paris, France. Since January 2008, Spepharm is also present in Europe through subsidiaries in Italy (Milan), Germany (Munich), The United-Kingdom (Oxford) and Denmark (Copenhagen) for the Nordic countries.
11
| Extinct | Pharmaceuticals: Major | 11 |
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy.
11
| Extinct | Biotechnology | 11 |
Centogene AG
 Centogene AG Medical/Nursing ServicesHealth Services Centogene AG focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders. The firm operates through the offices located in Freiburg, Dubai and Noida. The company was founded by Arndt Rolfs in 2006 and is headquartered in Rostock, Germany.
10
| Holding Company | Medical/Nursing Services | 10 |
NOXXON Pharma AG
 NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany.
9
| Subsidiary | Biotechnology | 9 |
DIREVO Biotech AG
 DIREVO Biotech AG Miscellaneous Commercial ServicesCommercial Services DIREVO Biotech AG researches on screening-based directed evolution of genes and proteins and applies its integrated proprietary technologies to the development of biopharmaceuticals, industrial enzymes, chemical biocatalysts and enzymes for food and feed. Its platform technologies combine efficient DNA variation methods for mutation and recombination of genes with ultra-high throughput screening technologies. The company was founded in 2000 and is headquartered in Cologne, Germany.
8
| Extinct | Miscellaneous Commercial Services | 8 |
AL-S Pharma AG
 AL-S Pharma AG Pharmaceuticals: MajorHealth Technology AL-S Pharma AG engages in the development and marketing of pharmaceutical products. The company was founded by Michael Salzmann on September 19, 2016 and is headquartered in Schlieren, Switzerland.
6
| Holding Company | Pharmaceuticals: Major | 6 |
leon-nanodrugs GmbH
 leon-nanodrugs GmbH Pharmaceuticals: MajorHealth Technology leon-nanodrugs GmbH develops oral and parenteral drugs. The firm's services include nanotechnology in medicine, MJR technology, pipeline, partnering with leon and leon network. The company was founded by Wolfgang Beier and Cornelia Beier in 2011 and is headquartered in Munich, Germany.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Zeneca Agrochemicals
3
| Extinct | 3 | |
SpePharm AG
 SpePharm AG Pharmaceuticals: MajorHealth Technology SpePharm AG acquires, registers, and markets medical value medicines for the hospital sector. Its brands include Dantrium IV, Dantrium, Dantamacrin, Lymphoseek and Mugard. The company was founded in 2012 and is headquartered in Luzern, Switzerland.
2
| Holding Company | Pharmaceuticals: Major | 2 |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
| Public Company | Biotechnology | 1 | |
Shire Orphan Therapies GmbH
 Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany.
1
| Subsidiary | Pharmaceuticals: Major | 1 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Hubert Birner via son réseau personnel
| Société | Secteur | Personnes liées | Poste principal |
|---|---|---|---|
| ELI LILLY AND COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Biotechnology | Director of Finance/CFO Human Resources Officer | |
| QIAGEN N.V. | Medical Specialties | Chief Executive Officer Corporate Officer/Principal | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
| BIOMARIN PHARMACEUTICAL INC. | Biotechnology | Corporate Officer/Principal Director/Board Member Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Sales & Marketing Comptroller/Controller/Auditor | |
Quintiles, Inc. (California)
 Quintiles, Inc. (California) Medical/Nursing ServicesHealth Services Quintiles, Inc. provides therapeutic services. It offers medical services, information and partnering solutions to the pharmaceutical, biotechnology and healthcare industries. The company was founded in 1982 and is headquartered in San Francisco, CA. | Medical/Nursing Services | Corporate Officer/Principal Director/Board Member | |
Emergent Product Development Seattle
 Emergent Product Development Seattle Pharmaceuticals: MajorHealth Technology Emergent Product Development Seattle discovers and develops biopharmaceutical products. It focuses on the discovery and development of novel medicines to treat inflammatory diseases and cancer. The company was founded by Peter A. Thompson, Jeffrey A. Ledbetter and Kendall M. Mohler in March 1999 and is headquartered in Seattle, WA. | Pharmaceuticals: Major | Chief Executive Officer Human Resources Officer | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Director/Board Member | |
| ZYLA LIFE SCIENCES | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Chief Executive Officer | |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Public Communications Contact | |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Graduate Degree Graduate Degree Graduate Degree | |
| Stanford University | College/University | Doctorate Degree Masters Business Admin | |
| EVOTEC SE | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member Chairman Director of Finance/CFO Chairman Chief Executive Officer | |
| RECORDATI | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Arrow Therapeutics Ltd.
 Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Boston College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| INSEAD | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of Vienna | College/University | Doctorate Degree Undergraduate Degree | |
Evotec International GmbH
 Evotec International GmbH Miscellaneous Commercial ServicesCommercial Services Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany. | Miscellaneous Commercial Services | Chief Executive Officer Chairman Founder | |
| University of St. Gallen | College/University | Graduate Degree Masters Business Admin | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer Chairman Chairman | |
Biovertis AG
 Biovertis AG Pharmaceuticals: MajorHealth Technology Biovertis AG operates as a clinical stage pharmaceutical company. It develops small molecule drugs against proprietary microbial antigens. The firm discovers and develops antimicrobial drugs for infections caused by antibiotic-resistant bacterial pathogens. The company was founded by Erich Felber, Uwe von Ahsen, and Alexander Ullrich von Gabain in 2003 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Basel | College/University | Corporate Officer/Principal Doctorate Degree | |
| University of Zurich | College/University | Corporate Officer/Principal Corporate Officer/Principal | |
| Freie Universität Berlin | College/University | Undergraduate Degree Undergraduate Degree Corporate Officer/Principal Undergraduate Degree | |
| The Johannes Gutenberg University of Mainz | College/University | Undergraduate Degree Doctorate Degree | |
| ABIONYX PHARMA | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Ludwig-Maximilians-Universität München | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| ARGENX SE | Pharmaceuticals: Other | Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| ISOFOL MEDICAL AB | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| SANA AB | Biotechnology | Chairman Director of Finance/CFO | |
| TME PHARMA N.V. | Biotechnology | Director/Board Member Chairman Director/Board Member Founder Chief Executive Officer Director/Board Member Chief Tech/Sci/R&D Officer | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Founder Founder | |
Access Vascular, Inc.
 Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Medical Specialties | Director/Board Member Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder Founder | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Chairman Director/Board Member | |
LEUKOCARE AG
 LEUKOCARE AG Medical/Nursing ServicesHealth Services LeukoCare AG develops protein stabilization and protection solutions. The firm specializes in the development of protein stabilization and protection solutions for biopharmaceuticals, vaccines, medical devices, and diagnostics technologies. Its service areas encompass technology licensing, prototyping and product development, clinical registration, biological and chemical testing, and consulting. The company was founded by Martin Scholz in 2001 and is headquartered in Munich, Germany. | Medical/Nursing Services | Director/Board Member Director/Board Member |
Statistiques
Internationale
| Etats-Unis | 16 |
| Allemagne | 10 |
| Suisse | 9 |
| Danemark | 5 |
| Pays-Bas | 4 |
Sectorielle
| Health Technology | 32 |
| Consumer Services | 12 |
| Commercial Services | 5 |
| Health Services | 4 |
| Communications | 2 |
Opérationnelle
| Director/Board Member | 494 |
| Corporate Officer/Principal | 146 |
| Chairman | 146 |
| Chief Executive Officer | 112 |
| Independent Dir/Board Member | 68 |
Relations les plus connectées
| Insiders | |
|---|---|
| Peer Schatz | 83 |
| Flemming Ørnskov | 34 |
| Michael Grey | 32 |
| Luc Marengère | 31 |
| Joseph deBethizy | 29 |
| Helmut Schühsler | 28 |
| Gerhard Ries | 27 |
| Denis Lucquin | 26 |
| Thomas D. Szucs | 23 |
| Berndt A. E. Modig | 23 |
| George Tidmarsh | 22 |
| Olivier Litzka | 21 |
| Stephen Aselage | 20 |
| Robert Radie | 18 |
| Michelle Griffin | 18 |
- Bourse
- Insiders
- Hubert Birner
- Connexions Sociétés
